Peptide Bloodwork Monitoring Protocol

Bloodwork is the only objective feedback mechanism for peptide protocols. Subjective improvements (better sleep, less joint pain, improved focus) are valuable but unreliable for detecting metabolic changes, hormonal shifts, or safety signals. This protocol covers what to test, when to test, and how to interpret results for each peptide class.

Universal baseline panel

Before starting any peptide protocol, order a comprehensive baseline. This panel applies regardless of which peptide you're using:

• Complete Blood Count (CBC) with differential — establishes immune cell baseline
• Comprehensive Metabolic Panel (CMP) — liver function (AST, ALT), kidney function (BUN, creatinine, eGFR), electrolytes, glucose
• Fasting glucose and fasting insulin — establish metabolic baseline; calculate HOMA-IR if insulin resistance is a concern
• HbA1c — 3-month average glucose control
• Lipid panel — total cholesterol, LDL, HDL, triglycerides
• Thyroid function — TSH, free T4 (baseline for metabolic assessment)

Draw this panel fasted (12 hours) in the morning. Keep the results — you will compare all future panels against this baseline.

GH secretagogue monitoring (CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, GHRP-2, GHRP-6, Hexarelin)

Additional markers

• IGF-1 — the primary readout of GH secretagogue effect. GH itself is pulsatile and difficult to measure meaningfully; IGF-1 reflects integrated GH activity over days.
• Fasting insulin — GH antagonizes insulin action. Monitor for rising fasting insulin as an early sign of insulin resistance.
• Prolactin — GHRP-2, GHRP-6, and Hexarelin can elevate prolactin. Ipamorelin and GHRH analogs (CJC-1295, Sermorelin) do not.
• Cortisol (AM) — GHRP-2 and GHRP-6 can increase cortisol secretion. Relevant if using these specific ghrelin mimetics.

Timing

Timepoint	What to draw	Purpose
Pre-protocol (baseline)	Universal panel + IGF-1, prolactin	Establish baselines
Week 4–6	IGF-1, fasting glucose, fasting insulin	Confirm GH response; early metabolic safety check
Week 12–16 (end of cycle)	IGF-1, fasting glucose, fasting insulin, HbA1c, CMP	Full safety assessment; inform cycling decision
4 weeks post-cycle	IGF-1	Confirm return to baseline during off period

Interpretation

• IGF-1 rises 20–50% above baseline but stays within age-appropriate reference range: Expected, favorable response. No intervention needed.
• IGF-1 exceeds upper reference range: Reduce dose. Supraphysiological IGF-1 carries theoretical mitogenic risk. The goal is optimization, not maximization.
• Fasting glucose rises > 100 mg/dL or fasting insulin rises > 15 μIU/mL: Developing insulin resistance. Consider dose reduction, adding metformin (with physician guidance), or discontinuing if values continue to climb.
• Prolactin elevation (GHRP-2/6/Hexarelin only): If prolactin exceeds the reference range, switch to Ipamorelin (cleanest ghrelin mimetic) or reduce GHRP dose.

GLP-1 agonist monitoring (Semaglutide, Tirzepatide, Liraglutide)

Additional markers

• Amylase and lipase — pancreatic enzymes. GLP-1 agonists carry a label warning for pancreatitis. Baseline and periodic monitoring is standard clinical practice.
• Thyroid function (TSH, free T4) — GLP-1 agonists carry a boxed warning for medullary thyroid carcinoma in rodents. Human relevance is debated, but thyroid monitoring is prudent.
• Calcitonin — if thyroid monitoring suggests abnormality. Elevated calcitonin can indicate medullary thyroid carcinoma.
• Kidney function (eGFR, creatinine) — GLP-1-associated nausea and vomiting can cause dehydration, stressing kidneys.

Timing

Timepoint	What to draw	Purpose
Pre-protocol	Universal panel + amylase, lipase, TSH	Baseline
Week 8 (after 2 dose titrations)	Fasting glucose, HbA1c, amylase, lipase, CMP	Metabolic response + pancreatic safety
Week 16–24 (target dose reached)	Full panel repeat: glucose, HbA1c, lipids, amylase, lipase, TSH, CMP	Comprehensive efficacy + safety assessment
Every 6 months on maintenance	HbA1c, lipids, TSH, amylase, lipase, CMP	Ongoing monitoring

Interpretation

• HbA1c drops 0.5–1.5% in diabetic/pre-diabetic users: Expected therapeutic response.
• Amylase or lipase > 3x upper limit of normal: Stop the GLP-1 agonist immediately. Evaluate for pancreatitis (imaging, clinical assessment).
• TSH changes or new thyroid nodule: Further evaluation with endocrinology. Not an indication to stop empirically, but requires investigation.
• Rising creatinine or declining eGFR: Assess hydration status. GLP-1-induced nausea can cause chronic low-grade dehydration that stresses kidneys.

Healing peptide monitoring (BPC-157, TB-500)

These peptides do not significantly affect hormonal axes or metabolic markers. Formal monitoring is less critical but still recommended for thoroughness.

Recommended markers

• CMP — liver and kidney function (confirm no unexpected organ stress)
• CBC — general health baseline
• Inflammatory markers (optional) — CRP, ESR. If tracking healing progress, declining inflammatory markers provide objective evidence.

Timing

Baseline + one follow-up at week 4–8. If no concerning changes, further monitoring is optional for these peptides specifically.

Immune peptide monitoring (Thymosin Alpha-1, Thymalin, LL-37, KPV)

Additional markers

• Lymphocyte subsets — CD4+ T cells, CD8+ T cells, CD4/CD8 ratio, NK cells (CD56+/CD16+). Available through specialized panels (lymphocyte subset analysis).
• Immunoglobulins — IgG, IgA, IgM. Measures humoral immune capacity.
• Inflammatory markers — CRP, ESR (particularly for KPV and anti-inflammatory peptides)

Timing

Timepoint	What to draw	Purpose
Pre-protocol	Universal panel + lymphocyte subsets + immunoglobulins	Establish immune baseline
Week 8–12	Lymphocyte subsets, CRP, CBC with differential	Assess immune response
Every 3–6 months on continuous Tα1	Lymphocyte subsets, CBC	Ongoing monitoring

Interpretation

• Improved CD4/CD8 ratio (from below 1.0 toward 1.5–2.5): Favorable response, indicating T-cell restoration.
• Increased NK cell count or activity: Favorable, particularly in immunosenescent individuals.
• Declining CRP (KPV users): Indicates anti-inflammatory effect is reaching the target.
• Unexpected lymphocyte elevation beyond reference range: Reassess — excessive immune stimulation may not be desirable.

Red flags — stop and evaluate

Regardless of which peptide you're using, these findings warrant immediate protocol cessation and medical evaluation:

• Fasting glucose > 126 mg/dL or HbA1c > 6.5% (new-onset diabetes range)
• Liver enzymes (AST or ALT) > 3x upper limit of normal (hepatotoxicity signal)
• Creatinine rising > 50% above baseline (renal stress)
• Amylase or lipase > 3x ULN (pancreatitis risk)
• Prolactin > 2x ULN with symptoms (galactorrhea, gynecomastia, menstrual disruption)
• IGF-1 > 1.5x the age-appropriate upper reference range (supraphysiological GH exposure)
• New thyroid nodule (in GLP-1 agonist users)

Practical notes

• Use the same lab for all panels. Reference ranges vary between labs; trends are only meaningful when measured on the same platform.
• Fasting protocol: 12-hour water-only fast before draws. Coffee, supplements, and peptide injections on the morning of the draw can distort results.
• Timing relative to peptide dosing: Draw blood at least 12 hours after the last peptide injection. For GH secretagogues dosed pre-sleep, a morning draw achieves this naturally.
• Direct-to-consumer lab options (Labcorp, Quest, Marek Health, etc.) can provide most of these panels without a physician requisition, though a physician review of results is always recommended.